

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

HCC38

RRID:CVCL_1267

Type: Cell Line

Proper Citation

RRID:CVCL_1267

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1267

Proper Citation: RRID:CVCL_1267

Description: Cell line HCC38 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12800145](#), [PMID:14762065](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:40300663](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC38

Synonyms: Hcc38, HCC-38, HCC 38, HCC0038, Hamon Cancer Center 38

Cross References: BTO:BTO_0005295, CLO:CLO_0003655, EFO:EFO_0001180, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2314, BioGRID_ORCS_Cell_line:871, BioSample:SAMN03471264, BioSample:SAMN10987659, cancercellines:CVCL_1267, CCRID:1101HUM-PUMC000220, Cell_Model_Passport:SIDM00675, ChEMBL-Cells:ChEMBL3308578, ChEMBL-Targets:ChEMBL1075460, CLS:305307, Cosmic:749717, Cosmic:904356, Cosmic:1018475, Cosmic:1047706, Cosmic:1136365, Cosmic:1235078, Cosmic:1287932, Cosmic:1430346, Cosmic:1460229, Cosmic:1518108, Cosmic:1603212, Cosmic:1935000, Cosmic:1995432, Cosmic:2009508, Cosmic:2164993, Cosmic-CLP:749717, DepMap:ACH-000276, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749717, GEO:GSM149979, GEO:GSM149987, GEO:GSM149995, GEO:GSM185085, GEO:GSM185086, GEO:GSM217579, GEO:GSM344382, GEO:GSM344432, GEO:GSM350536, GEO:GSM378150, GEO:GSM533398, GEO:GSM533405, GEO:GSM537968, GEO:GSM783968, GEO:GSM827244, GEO:GSM844013, GEO:GSM847390, GEO:GSM847487, GEO:GSM854621, GEO:GSM854622, GEO:GSM854623, GEO:GSM854624, GEO:GSM854625, GEO:GSM887054, GEO:GSM888124, GEO:GSM1008902, GEO:GSM1053702, GEO:GSM1172875, GEO:GSM1172967, GEO:GSM1214580, GEO:GSM1215289, GEO:GSM1215290, GEO:GSM1215291, GEO:GSM1215292, GEO:GSM1215293, GEO:GSM1215294, GEO:GSM1215295, GEO:GSM1215296, GEO:GSM1374511, GEO:GSM1401651, GEO:GSM1669859, IARC_TP53:10268, IGRhCellID:HCC38, KCLB:9S0038, LiGeA:CCLE_393, LINCS_HMS:50216, LINCS_LDP:LCL-1334, PharmacDB:HCC38_500_2019, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1267, PubChem_Cell_line:CVCL_1267, Wikidata:Q54881712

ID: CVCL_1267

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260815T233705+0000

Ratings and Alerts

No rating or validation information has been found for HCC38.

No alerts have been found for HCC38.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 382 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Shi J, et al. (2026) TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e20273.

Thiebaut C, et al. (2026) Targeting PRMTs Creates Vulnerability of DNA Double-Strand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC. *Cancer science*, 117(5), 1273.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Morinaga T, et al. (2026) A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis. *Oncogene*.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Fu Y, et al. (2025) 53BP1 regulates p53-E2F7-dependent transcriptional gene repression and participates in the Fanconi anemia pathway. *Cell reports*, 44(8), 116152.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. *International journal of cancer*, 156(8), 1606.

Xu W, et al. (2025) LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. *Molecular cancer research : MCR*, 23(10), 859.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Ludwig SD, et al. (2024) Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1. *Cell chemical biology*, 31(5), 904.

Dibra D, et al. (2024) Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. *Science advances*, 10(7), eadk1835.

Hirani P, et al. (2024) Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate. *Cancer research communications*, 4(4), 970.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. *iScience*, 27(2), 108958.

Massicano AVF, et al. (2023) [89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models. *Cancers*, 15(10).

Twomey JD, et al. (2023) Exploring the Role of Hypoxia-Inducible Carbonic Anhydrase IX (CAIX) in Circulating Tumor Cells (CTCs) of Breast Cancer. *Biomedicines*, 11(3).

Tian Y, et al. (2023) Akt3 promotes cancer stemness in triple-negative breast cancer through YB1-Snail/Slug signaling axis. *Genes & diseases*, 10(2), 301.